Company / Return on Equity (ROE)
10x Genomics, Inc. Return on Equity (ROE) History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-5.5%
FY2025
5-year range
-73.4% / -5.5%
FY2021-FY2025
Trend
+78.7%
vs FY2024
Sector context
#99 of 148
Health Care
What the data says
10x Genomics, Inc. reports negative total equity of -5.5% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-5.5% in FY2025 with a 5-year CAGR of +68.0%.
Improved from -34.4% to -5.5% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +68.0pp
- 5-Year Change
- +68.0pp
- 10-Year Change
- -
Sector benchmark
#99 of 148 in Health CareTop 67% of 148This company -5.5% Sector average -3.2%
▼
-73.2% below sector average
Key checks
Key Insights
- 10x Genomics, Inc.'s return on equity (roe) has grown for 3 consecutive years.
- In FY2025, return on equity (roe) increased 78.7% year-over-year.
- Currently 2.3pp below the Health Care sector average.
- Lowest return on equity (roe) in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.94 (distress zone, below 1.8 threshold)
- Negative profit margin: -29.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -5.5% | +78.7% |
| FY2024 | -25.7% | +25.3% |
| FY2023 | -34.4% | +53.1% |
| FY2022 | -73.4% | -887.0% |
| FY2021 | -7.4% | +89.9% |
| FY2020 | -73.4% | -887.0% |
| FY2019 | -7.4% | - |
| FY2018 | - | - |
| FY2017 | - | - |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026